AV 203

Drug Profile

AV 203

Alternative Names: AV-203; CAN-017

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; CANbridge Life Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Oesophageal cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 11 Aug 2016 CANbridge Life Sciences and Boehringer Ingelheim enter into an agreement for manufacture of AV 203 for phase II trial in Oesophageal cancer
  • 11 Aug 2016 CANbridge Life Sciences plans a phase IIa trial in Oesophageal cancer in Greater China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top